Brooks Moore & Associates’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.17M | Buy |
32,419
+1,650
| +5% | +$193K | 1.87% | 16 |
|
|
2026
Q1 | $3.7M | Sell |
30,769
-1,415
| -4% | -$163K | 1.86% | 18 |
|
|
2025
Q4 | $3.39M | Sell |
32,184
-15
| -0% | -$1.41K | 1.67% | 20 |
|
|
2025
Q3 | $2.7M | Sell |
32,199
-14,957
| -32% | -$1.23M | 1.37% | 24 |
|
|
2025
Q2 | $3.68M | Sell |
47,156
-425
| -0.9% | -$33.8K | 1.99% | 18 |
|
|
2025
Q1 | $4.27M | Sell |
47,581
-175
| -0.4% | -$16.3K | 2.41% | 12 |
|
|
2024
Q4 | $4.75M | Buy |
47,756
+220
| +0.5% | +$22.7K | 2.81% | 10 |
|
|
2024
Q3 | $5.4M | Buy |
47,536
+406
| +0.9% | +$48.2K | 3.19% | 7 |
|
|
2024
Q2 | $5.83M | Sell |
47,130
-395
| -0.8% | -$50.9K | 3.75% | 4 |
|
|
2024
Q1 | $6.27M | Sell |
47,525
-49
| -0.1% | -$6.04K | 4.02% | 3 |
|
|
2023
Q4 | $5.19M | Sell |
47,574
-168
| -0.4% | -$17.4K | 3.56% | 6 |
|
|
2023
Q3 | $4.92M | Buy |
47,742
+1,312
| +3% | +$141K | 3.71% | 5 |
|
|
2023
Q2 | $5.36M | Sell |
46,430
-225
| -0.5% | -$25.5K | 3.77% | 4 |
|
|
2023
Q1 | $4.96M | Buy |
46,655
+1,856
| +4% | +$200K | 3.57% | 4 |
|
|
2022
Q4 | $4.97M | Sell |
44,799
-761
| -2% | -$77.8K | 3.63% | 6 |
|
|
2022
Q3 | $3.92M | Sell |
45,560
-577
| -1% | -$51.5K | 3.17% | 7 |
|
|
2022
Q2 | $4.21M | Sell |
46,137
-975
| -2% | -$86.4K | 3.03% | 8 |
|
|
2022
Q1 | $3.87M | Sell |
47,112
-725
| -2% | -$57.2K | 2.37% | 11 |
|
|
2021
Q4 | $3.67M | Sell |
47,837
-250
| -0.5% | -$19.9K | 2.15% | 16 |
|
|
2021
Q3 | $3.61M | Buy |
48,087
+75
| +0.2% | +$5.7K | 2.36% | 10 |
|
|
2021
Q2 | $3.73M | Buy |
48,012
+4,268
| +10% | +$317K | 2.38% | 8 |
|
|
2021
Q1 | $3.22M | Buy |
43,744
+5,324
| +14% | +$393K | 2.18% | 14 |
|
|
2020
Q4 | $3M | Buy |
38,420
+655
| +2% | +$50.1K | 2.32% | 12 |
|
|
2020
Q3 | $2.99M | Sell |
37,765
-652
| -2% | -$51.1K | 2.58% | 9 |
|
|
2020
Q2 | $2.83M | Buy |
38,417
+1,727
| +5% | +$130K | 2.65% | 8 |
|
|
2020
Q1 | $2.69M | Sell |
36,690
-524
| -1% | -$41.2K | 2.86% | 5 |
|
|
2019
Q4 | $3.23M | Buy |
37,214
+1,208
| +3% | +$99.2K | 2.56% | 6 |
|
|
2019
Q3 | $2.89M | Buy |
36,006
+592
| +2% | +$47.4K | 2.44% | 6 |
|
|
2019
Q2 | $2.83M | Buy |
35,414
+941
| +3% | +$72.1K | 2.43% | 8 |
|
|
2019
Q1 | $2.74M | Sell |
34,473
-592
| -2% | -$44.3K | 2.5% | 9 |
|
|
2018
Q4 | $2.56M | Buy |
+35,065
| New | +$2.48M | 2.57% | 7 |
|
Other funds holding MRK
Brooks Moore & Associates's MRK Position: Q2 2026 in Review
Brooks Moore & Associates increased its Merck (MRK) stake by 5.4% in Q2 2026, buying an estimated $193K and bringing the position to 32,419 shares worth $4.17M. The position accounts for 1.87% of the portfolio, ranked #16.
Brooks Moore & Associates first reported a position in MRK in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.27M in Q1 2024. 3,841 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Brooks Moore & Associates held 32,419 shares of Merck worth $4.17M as of Q2 2026.
- Brooks Moore & Associates bought 1,650 Merck shares in Q2 2026, an estimated $193K.
- Merck made up 1.87% of Brooks Moore & Associates's portfolio in Q2 2026, its #16 holding.
- Brooks Moore & Associates first reported a position in Merck in Q4 2018 and has held it in 31 quarters since.
- Brooks Moore & Associates's Merck position peaked at $6.27M in Q1 2024.
- 3,841 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Brooks Moore & Associates's 13F filing for Q2 2026, filed 17 Aug 2026.